A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
Original Article: Liquid biopsies could be used as new predictive marker for metastatic TNBC